Diapositiva 1

1
BioSpain 2006
2
www.spiderbiotech.com
Who we are
SpiderBiotech is a biotechnology start-up company
engaged in the discovery and development of
therapeutic multimeric peptides in the field of
bacterial infections. The company was established
in 2006.
BioSpain September 19, 2006 www.spiderbiotech.com
3
The Arsenal of Antibacterial Agents

• Most antimicrobial molecules are produced by
  other microbes or semi-synthetic derivatives of
  antibiotics.
• Only two classes of antimicrobials were derived
  solely from synthetic-chemistry efforts the
  fluoroquinolones and the oxazolidinones.
• Resistance has emerged for all classes of
  antimicrobial therapeutics.

BioSpain September 19, 2006 www.spiderbiotech.com
4
Antimicrobial Peptides Novel Weapons Against
Antibiotic-Resistant Bacteria?
Stimulate innate and adaptive immuno
response Cause autolytic enzyme release Block
cell wall envelope synthesis Permeabilize/damage
membrane Block internal metabolic process
Zasloff M., Nature, 415, 389-395
BioSpain September 19, 2006 www.spiderbiotech.com
5
What We Do

• 1. Development of a panel of drug candidates
  based on SB006, active against
• Escherichia coli,
• Klebsiella pneumoniae,
• Enterobacter spp.
• Pseudomonas aeruginosa,
• including clinical isolates showing a multi drug
  resistant phenotype.
• 2. Optimisation SB006 with a rational approach.
• 3. Pre-clinical trials of SB006.

BioSpain September 19, 2006 www.spiderbiotech.com
6
Advantages of Multimeric Short Peptides

• MAP (Multiple Antigen Peptides) contains a
  multivalent core that tethers an array of
  branching peptides.
• MAP are stable to proteolysis respect to linear
  peptides (Bracci L. et al J.B.C. 2003 Lozzi L.
  et al. Chem. Biol. 2003).
• Dendrimeric design increases the local
  concentration of peptidic units and decreases the
  entropy of self-assembly.

BioSpain September 19, 2006 www.spiderbiotech.com
7
Our Candidates
BioSpain September 19, 2006 www.spiderbiotech.com
8
Resistance Induction in Vitro
Amram Mor, Drug Development Research (2000)
Indution of resistance measured as MIC (µg/ml) of
SB006 against P. aeruginosa ATCC27853 treated for
10 passages with one-half the initial MIC. SB006
showed a modest two-fold increase in resistance.
BioSpain September 19, 2006 www.spiderbiotech.com
9
Why

• Antibacterial market is large and growing.
• A faster and easier drug development process.
• Antibiotic resistance is an urgent and growing
  problem.
• Due to their mechanism of action there is little
  chance for a microbe to survive antimicrobial
  peptides killing activity and develop
  resistance.
• Lack of pipeline compounds.
• Drugs in earlier development focused on hospital
  multiresistant Gram-positive indications compared
  to agents for Gram-negative infection.

BioSpain September 19, 2006 www.spiderbiotech.com
10
Gram Negatives Bad Bugs Need Drugs
Surgical site infections 34
Urinary tract infections 71
Increasing antibiotic resistance
No agents against G- under development
Bacteremia 24
J. G. Bartlett Antibacterial Drug Resistance
December 2005
No agents under development exhibit
comprehensive activity against difficult
Gram-negative bacteria such as Pseudomonas,
Klebsiella, Acinetobacter and Burkholderia spp.
BioSpain September 19, 2006 www.spiderbiotech.com
11
What We Seek

• Short-term objectives to complete the
  preclinical development and file an
  Investigational New Drug (IND) application for
  SB006 and/or its optimized derivatives within two
  years.
• Long-term objectives to exploit the unique
  properties of polyvalent peptides in MAP form
  combined with the Phage Display technology to
  produce successful products and new generations
  of drugs faster and more cheaply.
• We actively seek strategic alliances with
  academic institutions or other biotechnology
  companies to build a critical mass of research.

BioSpain September 19, 2006 www.spiderbiotech.com
12
Contacts
Andrea Giuliani - CEO agiuliani_at_spiderbiotech.com
Tel [phone] www.spiderbiotech.com